FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141799286> ?p ?o ?g. }

• W3141799286 abstract "Abstract Background Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of Hodgkin lymphoma. There is limited data on treatment, management of refractory and relapsed disease, and long-term outcome. Many registries or country-wide data reports are unable to provide detailed primary and subsequent management. We are reporting our observation on patient’s characteristics, management, and outcome. Methods This single-institution retrospective cohort analysis includes NLPHL patients seen from 1998 to July 2019. We used Fisher’s exact test, chi-square, and Kaplan-Meier (KM) method for various analyses. Results Two hundred patients were identified, (6.34% of all the HL). Male:female was 3:1. The median age at diagnosis was 22 years (4–79 years). Stage I-II in 145 (72.5%) cases. One hundred patients (50%) received chemotherapy, 68 (34%) chemotherapy + radiation therapy (RT); 87% of all chemotherapy was ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Thirteen patients (6.5%) received RT alone and 16 (8%) had surgery alone. Complete response in 82%, partial response in 5.5% and progressive disease in 10.5%. The median follow is 60 months (5–246). Median 5 and 10 years overall survival (OS) is 94.8 and 92.4% (stages I-II, 97.7 and 97.7%, stage III-IV, 94.8 and 92.4%). Median event-free survival (EFS) is 62.3 and 54% respectively (stage I-II, 72 and 64%, stage III-IV, 36.4 and 18.2%). Stage I-II vs III-IV OS ( p = < 0.001) and EFS ( p = < 0.001) were significant. For stage I-II, 5 year EFS of chemotherapy + RT (83.3%) was superior to chemotherapy alone (60%, p = 0.008). Five year EFS for early favorable (80%), early unfavorable (60%), and advanced (36.4%) was significant ( p = < 0.001). Eleven patients (5.5%) had high-grade transformation. Twenty-nine patients underwent HDC auto-SCT, all are alive (28 in remission). 25% of patients had pathologically proved nodal hyperplasia at some point in time. Conclusion OS of NLPHL is excellent and independent of treatment type. EFS is better for chemotherapy + RT than chemotherapy alone. Stem cell transplant in refractory / multiple relapses resulted in excellent disease control. There is a need to identify optimal treatment strategies accordingly to the risk stratification." @default.
• W3141799286 created "2021-04-13" @default.
• W3141799286 creator A5014511073 @default.
• W3141799286 creator A5020978628 @default.
• W3141799286 creator A5042696306 @default.
• W3141799286 creator A5043248446 @default.
• W3141799286 creator A5045947735 @default.
• W3141799286 creator A5058750733 @default.
• W3141799286 creator A5061557104 @default.
• W3141799286 creator A5067532175 @default.
• W3141799286 creator A5073864168 @default.
• W3141799286 creator A5076449054 @default.
• W3141799286 creator A5077257911 @default.
• W3141799286 creator A5080656724 @default.
• W3141799286 creator A5089319089 @default.
• W3141799286 date "2021-04-01" @default.
• W3141799286 modified "2023-09-27" @default.
• W3141799286 title "Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East" @default.
• W3141799286 cites W1796898812 @default.
• W3141799286 cites W1819862099 @default.
• W3141799286 cites W1901364009 @default.
• W3141799286 cites W1912693401 @default.
• W3141799286 cites W1939533304 @default.
• W3141799286 cites W1969237572 @default.
• W3141799286 cites W1972497571 @default.
• W3141799286 cites W1980374437 @default.
• W3141799286 cites W2006625003 @default.
• W3141799286 cites W2016047292 @default.
• W3141799286 cites W2020063695 @default.
• W3141799286 cites W2026904790 @default.
• W3141799286 cites W2045399297 @default.
• W3141799286 cites W2054468708 @default.
• W3141799286 cites W2070593592 @default.
• W3141799286 cites W2107202569 @default.
• W3141799286 cites W2119147717 @default.
• W3141799286 cites W2123902519 @default.
• W3141799286 cites W2142278289 @default.
• W3141799286 cites W2147657290 @default.
• W3141799286 cites W2151558804 @default.
• W3141799286 cites W2181228347 @default.
• W3141799286 cites W2253668567 @default.
• W3141799286 cites W2310716991 @default.
• W3141799286 cites W2591535170 @default.
• W3141799286 cites W2736629850 @default.
• W3141799286 cites W2764270814 @default.
• W3141799286 cites W2768402498 @default.
• W3141799286 cites W2911692028 @default.
• W3141799286 cites W2962762991 @default.
• W3141799286 cites W2980270189 @default.
• W3141799286 cites W2980810865 @default.
• W3141799286 cites W2988215584 @default.
• W3141799286 cites W2789544671 @default.
• W3141799286 doi "https://doi.org/10.1186/s12885-021-08074-2" @default.
• W3141799286 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8017738" @default.
• W3141799286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33794818" @default.
• W3141799286 hasPublicationYear "2021" @default.
• W3141799286 type Work @default.
• W3141799286 sameAs 3141799286 @default.
• W3141799286 citedByCount "1" @default.
• W3141799286 countsByYear W31417992862021 @default.
• W3141799286 crossrefType "journal-article" @default.
• W3141799286 hasAuthorship W3141799286A5014511073 @default.
• W3141799286 hasAuthorship W3141799286A5020978628 @default.
• W3141799286 hasAuthorship W3141799286A5042696306 @default.
• W3141799286 hasAuthorship W3141799286A5043248446 @default.
• W3141799286 hasAuthorship W3141799286A5045947735 @default.
• W3141799286 hasAuthorship W3141799286A5058750733 @default.
• W3141799286 hasAuthorship W3141799286A5061557104 @default.
• W3141799286 hasAuthorship W3141799286A5067532175 @default.
• W3141799286 hasAuthorship W3141799286A5073864168 @default.
• W3141799286 hasAuthorship W3141799286A5076449054 @default.
• W3141799286 hasAuthorship W3141799286A5077257911 @default.
• W3141799286 hasAuthorship W3141799286A5080656724 @default.
• W3141799286 hasAuthorship W3141799286A5089319089 @default.
• W3141799286 hasBestOaLocation W31417992861 @default.
• W3141799286 hasConcept C126322002 @default.
• W3141799286 hasConcept C141071460 @default.
• W3141799286 hasConcept C146357865 @default.
• W3141799286 hasConcept C151730666 @default.
• W3141799286 hasConcept C2776232574 @default.
• W3141799286 hasConcept C2776305933 @default.
• W3141799286 hasConcept C2776694085 @default.
• W3141799286 hasConcept C2776755627 @default.
• W3141799286 hasConcept C2777132456 @default.
• W3141799286 hasConcept C2778336483 @default.
• W3141799286 hasConcept C2779338263 @default.
• W3141799286 hasConcept C2779429289 @default.
• W3141799286 hasConcept C2780964509 @default.
• W3141799286 hasConcept C509974204 @default.
• W3141799286 hasConcept C71924100 @default.
• W3141799286 hasConcept C86803240 @default.
• W3141799286 hasConcept C90924648 @default.
• W3141799286 hasConceptScore W3141799286C126322002 @default.
• W3141799286 hasConceptScore W3141799286C141071460 @default.
• W3141799286 hasConceptScore W3141799286C146357865 @default.
• W3141799286 hasConceptScore W3141799286C151730666 @default.
• W3141799286 hasConceptScore W3141799286C2776232574 @default.
• W3141799286 hasConceptScore W3141799286C2776305933 @default.
• W3141799286 hasConceptScore W3141799286C2776694085 @default.
• W3141799286 hasConceptScore W3141799286C2776755627 @default.

• next